Trial Profile
A phase 1 clinical study evaluating HER2-cVLP cancer vaccine for breast cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs ES2B C001 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 13 Sep 2022 New trial record
- 02 Sep 2022 According to an AdaptVac media release, this trial is expected to start in 2024.